BACKGROUND: The invasiveness of tumor cells depends in large part on their motility, which in turn depends on cytoskeletal function. A major cytoskeletal component involved in cell motility is myosin II, the classical form of myosin first identified in muscle but also expressed in nonmuscle cells. Myosin II is activated by myosin light chain kinase (MLCK), which phosphorylates it on its regulatory light chain. In this context, the contribution made by MLCK to tumor cell motility and invasiveness has been investigated extensively in vitro, but clinical evidence of such a contribution has been lacking. In the present study, therefore, we examined the role of MLCK in the metastasis of non-small cell lung cancer (NSCLC) in a clinical setting. METHODS: We measured MLCK mRNA expression in tumor samples from 39 NSCLC patients using real-time semiquantitative reverse transcription polymerase chain reaction carried out in a LightCycler. We then correlated MLCK mRNA expression with known clinicopathological factors. RESULTS: We found that levels of MLCK mRNA expression were higher in patients who showed disease recurrence and distant metastasis than in those who did not. Moreover, the 3-year disease-free survival rate among patients showing lower levels of MLCK mRNA expression [log10(MLCK/GAPDH) <1.4] was significantly greater than among those showing higher MLCK mRNA expression [log10(MLCK/GAPDH) > or =1.4] (87.5 vs. 50.0%; log-rank test, p = 0.021). CONCLUSION: These findings are the first clinical evidence that expression of MLCK is correlated with disease recurrence and distant metastasis in NSCLC.
BACKGROUND: The invasiveness of tumor cells depends in large part on their motility, which in turn depends on cytoskeletal function. A major cytoskeletal component involved in cell motility is myosin II, the classical form of myosin first identified in muscle but also expressed in nonmuscle cells. Myosin II is activated by myosin light chain kinase (MLCK), which phosphorylates it on its regulatory light chain. In this context, the contribution made by MLCK to tumor cell motility and invasiveness has been investigated extensively in vitro, but clinical evidence of such a contribution has been lacking. In the present study, therefore, we examined the role of MLCK in the metastasis of non-small cell lung cancer (NSCLC) in a clinical setting. METHODS: We measured MLCK mRNA expression in tumor samples from 39 NSCLCpatients using real-time semiquantitative reverse transcription polymerase chain reaction carried out in a LightCycler. We then correlated MLCK mRNA expression with known clinicopathological factors. RESULTS: We found that levels of MLCK mRNA expression were higher in patients who showed disease recurrence and distant metastasis than in those who did not. Moreover, the 3-year disease-free survival rate among patients showing lower levels of MLCK mRNA expression [log10(MLCK/GAPDH) <1.4] was significantly greater than among those showing higher MLCK mRNA expression [log10(MLCK/GAPDH) > or =1.4] (87.5 vs. 50.0%; log-rank test, p = 0.021). CONCLUSION: These findings are the first clinical evidence that expression of MLCK is correlated with disease recurrence and distant metastasis in NSCLC.
Authors: Dalit Barkan; Hynda Kleinman; Justin L Simmons; Holly Asmussen; Anil K Kamaraju; Mark J Hoenorhoff; Zi-yao Liu; Sylvain V Costes; Edward H Cho; Stephen Lockett; Chand Khanna; Ann F Chambers; Jeffrey E Green Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: J Maeda; T Hirano; A Ogiwara; S Akimoto; T Kawakami; Y Fukui; T Oka; Y Gong; R Guo; H Inada; K Nawa; M Kojika; Y Suga; T Ohira; K Mukai; H Kato Journal: Br J Cancer Date: 2008-01-22 Impact factor: 7.640